Pembrolizumab + Idelalisib for Lung Cancer Study

Summary

This is a phase 1b/2 study to determine the safety and effectiveness of the combination of pembrolizumab and idelalisib in NSCLC patients whose disease has stopped responding to immune therapy. This study is being done to see if adding another immune modulator (idelalisib) to standard pembrolizumab will increase response rates, compared to the response seen with pembrolizumab alone.

Timeline

Start

2017-09-26

Primary completion

2020-08-15

Completion

2021-08-25

Drugs

Indications